Clinical Trials Law Programs Therapy 
Cannabis Law Report
JUNE 16, 2021
Both parties to this new relationship are committed to excellence in clinical research and patient access to psychedelic medicine with a focus on naturally derived psilocybin. . This relationship enables us to initiate our clinical research program and marks an important step for Wake in Canada. ABOUT SANTÉ CANNABIS.
Cannabis Law Report
JULY 21, 2021
The study is expected to be the world’s first Phase 2a clinical trial evaluating the efficacy of psilocybin and psychotherapy to treat fibromyalgia. The open-label Phase 2a clinical trial will evaluate the efficacy of TRYP-8802, an oral formulation of synthetic psilocybin, in tandem with psychotherapy for treating fibromyalgia.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Cannabis Law Report
SEPTEMBER 2, 2022
The clinical trial involving the use of Filament’s psilocybin received approval from Health Canada and was conducted as part of ATMA Journey Centre’s psychedelic-assisted therapist training program. was the first Canadian private company to engage in legally authorized psilocybin-assisted therapy.
Cannabis Law Report
MAY 19, 2022
This is Numinus’ first psilocybin-assisted therapy treatment outside of ongoing clinical trials, and among the first to use of this regulatory mechanism through Health Canada’s Special Access Program (“SAP”), which was amended January 5 th , 2022 to include access to psychedelic compounds on a case-by-case basis.
Canna Law Blog
NOVEMBER 27, 2021
is expanding rapidly as numerous neuropharmaceutical companies look to be among the first-to-market potentially revolutionary therapies. In fact, Small Pharma has been conducting trials as reported by the BBC and expanded its clinical trial this past summer. California Psychedelic Law Update.
Canna Law Blog
NOVEMBER 10, 2020
I was talking to another lawyer about last week’s vote by Oregonians to legalize psilocybin therapy here in the state. Public Law 115-176 (“Right to Try”) is a federal law enacted in 2018 that creates a uniform system for terminal patients seeking access to investigational treatments.
Cannabis Law Report
JULY 13, 2022
Their position as therapeutic practitioners, as well as their work in conducting the kind of clinical trials necessary to advance regulatory outcomes for psychedelic medicines, make them ideal partners in alignment with Optimi’s strategic goals.”. VANCOUVER, British Columbia, July 13, 2022 (GLOBE NEWSWIRE) — Optimi Health Corp. (
Expert insights. Personalized for you.
104 
Let's personalize your content